Botanix Pharmaceuticals

Unlocking the potential of synthetic cannabinoids

Pharmaceutical company leveraging the unique properties of synthetic cannabinoids with its Permetrex™ technology

Promising R&D, with a rapidly advancing pipeline of dermatology and antimicrobial products

World-class team with extensive cannabinoid drug development and commercialisation expertise

Evidence, first

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. We have attracted a world-class team and significant capital to support the progression of our products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA). Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach.

Check out our latest news

CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’

Groundbreaking new research has found synthetic cannabidiol…

Qld researchers on how cannabis could be used to fight superbug

Queensland researchers are studying a component of medicinal…

Journal article | “The antimicrobial potential of cannabidiol”

An important research project testing the targeted capabilities…

Oxford research tackles threat of antibiotic resistance

Oxford University is opening a new research institute dedicated…

UQ media release | Research establishes antibiotic potential for cannabis molecule

Synthetic cannabidiol, better known as CBD, has been shown for…

Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that

Superbugs were this week labelled as “the next great health…

Antibiotic resistance: a matter of time

"Is this just a projection...?"  The narrator of this…

Botanix Pharmaceuticals updates on meeting with FDA

AusBiotech's BiotechDispatch featured our BTX 1801 antimicrobial…

Invest in innovation

Botanix Pharmaceuticals offers a compelling opportunity for investors who are interested in capitalising on the clinical potential of synthetic cannabinoids. Our clinical trials to date have highlighted the unique mechanism of action which drives synthetic cannabidiol to produce anti-inflammatory and antimicrobial effects. We are leveraging this evidence to inform the development of new pharmaceutical products, targeting some of the most underserved and lucrative segments of the global healthcare market. Already, we have one of the most advanced clinical pipelines for synthetic cannabinoids in the world.

New treatments, in demand

Botanix has generated strong scientific support for the anti-inflammatory and antimicrobial mechanisms of action of synthetic cannabinoids with application in the development of novel dermatology and bacteria fighting applications.

There have been no new chemical entities (NCE’s) in topical drugs approved for acne in more than two decades and resistance to available antibiotics remains a significant global issue, with no new classes of antibiotics approved in more than three decades. When bacteria survive exposure to antibiotics that would normally eliminate them, these surviving bacteria grow and spread resistance, leading to the emergence of ‘superbugs’. New treatments in dermatology and anti-microbials are needed now.

Botanix periodically runs clinical studies in Australia, New Zealand the USA. Share your details if you would like to learn more.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere